MedTrace Logo

Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers

NCT06304129 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 189

Last updated 2024-03-12

No results posted yet for this study

Summary

.The goal of this interventional study is to estimate the diagnostic performance of plasma biomarkers of interest (Aβ40 and Aβ42, P-Tau and NFL), enabling discrimination between patients with and without a pathophysiological AD process. The main questions it aims to answer are:

* to define a threshold value for each of the plasma,
* to describe the correlations between the plasma biomarkers of interest and the other biological analyses performed as part of care, in particular triglyceridemia, cholesterolemia, glycemia and proteinemia,
* to describe biomarker results in relation to comorbidities, in particular dyslipidemia and diabetes
* to describe the final diagnosis and results obtained for plasma biomarkers, for patients with intermediate results according to the A/T/N classification (A-/T+ or A+/T-) Participants will be selected among patients undergoing lumbar puncture for the differential diagnosis of AD at Nancy University Hospital.

Conditions

  • Alzheimer Blood Biomarkers

Interventions

DIAGNOSTIC_TEST

Blood ponction

Blood ponction

Sponsors & Collaborators

  • Thérèse Jonveaux

    collaborator UNKNOWN

  • Laure Joly

    collaborator UNKNOWN

  • Lucie Hopes

    collaborator UNKNOWN

  • Maia Simon

    collaborator UNKNOWN

  • Franck Schreiner

    collaborator UNKNOWN

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Catherine Malaplate, PhD, PharmD · CHRU Nancy

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-02
Primary Completion
2026-01-02
Completion
2026-09-02

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06304129 on ClinicalTrials.gov